Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 04, 2023 08:00 ET | Source: Protara Therapeutics

Protara Therapeutics Announces First Quarter 2023 Financial Results and Business Update

Favorable tolerability and anti-tumor activity observed in NMIBC patients treated with TARA-002 in ADVANCED-1 trialCompany plans to initiate ADVANCED-2 trial in BCG-naïve CIS patients and...
May 02, 2023 08:00 ET | Source: Protara Therapeutics

Protara Therapeutics Receives Regulatory Clearance from FDA to Commence Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations

STARBORN-1 trial leverages data from TARA-002 predecessor therapy OK-432, which is approved and has treated thousands of pediatric patients with Lymphatic Malformations in Japan and Taiwan as well as...
April 28, 2023 08:00 ET | Source: Protara Therapeutics

Protara Therapeutics Announces Positive Preliminary Data from ADVANCED-1 Phase 1a Dose Escalation Trial of TARA-002 in NMIBC Supporting Advancement into Phase 2 Clinical Development

Favorable tolerability observed in patients with NMIBC treated with TARA-002 in ADVANCED-1 trialAnti-tumor activity was observed in all three evaluable patients with CIS, including one heavily...
March 08, 2023 08:00 ET | Source: Protara Therapeutics

Protara Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

- Data from Phase 1a Portion of ADVANCED-1 Trial of TARA-002 for the Treatment of Non-Muscle Invasive Bladder Cancer Expected in 2Q23 – - Start up Activities for Phase 2 Trial of TARA-002 in...
March 01, 2023 08:00 ET | Source: Protara Therapeutics

Protara Therapeutics to Participate in Upcoming Investor Conferences

NEW YORK, March 01, 2023 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases,...
February 02, 2023 08:00 ET | Source: Protara Therapeutics

Protara Therapeutics to Present at the Guggenheim Healthcare Talks Oncology Day

NEW YORK, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases,...
January 30, 2023 08:00 ET | Source: Protara Therapeutics

Protara Therapeutics Announces Appointment of Patrick Fabbio as Chief Financial Officer

NEW YORK, Jan. 30, 2023 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases,...
December 01, 2022 08:00 ET | Source: Protara Therapeutics

Protara Therapeutics Announces Trials in Progress Poster Presentation for the ADVANCED-1 Trial in NMIBC at the 23rd Annual Meeting of the Society of Urologic Oncology

NEW YORK, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases,...
November 03, 2022 08:00 ET | Source: Protara Therapeutics

Protara Therapeutics Announces Third Quarter 2022 Financial Results and Business Overview

- Dose Escalation Ongoing in Phase 1 ADVANCED-1 Study of TARA-002 for the Treatment of Non-Muscle Invasive Bladder Cancer - - Following Recent Feedback from the U.S. Food and Drug Administration,...
September 06, 2022 08:00 ET | Source: Protara Therapeutics

Protara Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference

NEW YORK, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases,...